Cancer Biomarkers Market Size, Share – Industry Report 2022
According to research report the global cancer biomarkers market to reach USD 20.4 billion by 2022, at a CAGR of 12.2%
(IINews) - The increasing prevalence of cancer, rising government support for research on cancer biomarkers, growing use of biomarkers in drug discovery and development, and increasing use of biomarker tests for diagnostic purposes are the major factors that are driving the growth of this market.
Market Size -
According to research report the global cancer biomarkers market to reach USD 20.4 billion by 2022. and is estimated to grow at a CAGR of 12.2% during the forecast period. The APAC region is projected to register the highest CAGR during the forecast period. The APAC market for cancer biomarkers has witnessed significant growth due to increasing demand for better healthcare services in developing economies such as India and China.
Read More: https://www.marketsandmarkets.com/PressReleases/oncology-biomarkers-market.asp
In this report, the market is segmented into biomarker type, cancer type, profiling technology, application, and region.
• On the basis of biomarker type, the cancer biomarkers market segmented into protein biomarker, genetic biomarker, and other biomarkers include cell, viral, and carbohydrate biomarkers. The genetic biomarkers segment is expected to register the highest CAGR during the forecast period. The high growth rate of this segment can be attributed to the increasing advancements in genomics technologies and the rising adoption of high-throughput sequencing technologies in biomarker discovery and development.
• The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin’s lymphoma, kidney, and other cancers including multiple myeloma, cervical, central nervous system cancer, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancer. During the forcast period, the lung cancer segment is expected to register the highest CAGR. The high growth rate of this segment can be attributed to the increasing research focus on lung cancer biomarkers by market players.
• On the basis of application, the cancer biomarkers market is classified into diagnostics, research and development, prognostics, risk assessment, and other applications such as personalized medicine, surrogate endpoints, and therapeutics. The research and development application segment is estimated to register the highest CAGR during the forecast period. Pharmaceutical and biotech companies are increasingly focusing on the use of biomarkers in their drug discovery and development process and have formed strategic alliances for sharing technology for biomarker applications in large-stage clinical trials, which is fueling the growth of this market.
• The cancer biomarkers market on the basis of profiling technology is segmented into omics technology, imaging technology, immunoassays, bioinformatics, and cytogenetics. The omics technologies segment is expected to register the highest CAGR during the forecast period. The high growth rate of this segment can be attributed to the increasing adoption of advanced omics technologies for cancer detection and drug discovery & development applications, especially in developing countries. Advances in high-throughput omics technologies are also contributing to the growth of this market by increasing the space of prospective biomarkers in cancer research.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202
The major players operating in the cancer biomarkers market are Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson and Company (US), and Hologic (US).
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
newsletter(at)marketsandmarkets.com
Themen in diesem Fachartikel:
Unternehmensinformation / Kurzprofil:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Datum: 17.10.2019 - 14:16 Uhr
Sprache: Deutsch
News-ID 1762952
Anzahl Zeichen: 0
Kontakt-Informationen:
Ansprechpartner:
Stadt:
Telefon:
Kategorie:
Gesundheit & Medizin
Anmerkungen:
Dieser Fachartikel wurde bisher 61 mal aufgerufen.
Der Fachartikel mit dem Titel:
"Cancer Biomarkers Market Size, Share – Industry Report 2022
"
steht unter der journalistisch-redaktionellen Verantwortung von
MarketsandMarkets™ INC. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).